Abstract PO1-17-08: Post-approval treatment patterns and tolerability of neratinib in HER2+ early-stage breast cancer
K McCann, N Harbeck, D Tripathy, A Chan, J Andersen… - Cancer Research, 2024 - AACR
Background: While the approval status for neratinib in HER2+ early-stage breast cancer
(EBC) allows its use following any trastuzumab-based therapy, the phase 3 ExteNET trial …
(EBC) allows its use following any trastuzumab-based therapy, the phase 3 ExteNET trial …
[HTML][HTML] 98P Real-world effectiveness and safety of neratinib in the extended adjuvant treatment of patients with HER2+ early breast cancer (eBC) in the United States …
DI Lüftner, J O'Shaughnessy, A Zkik, O Dialla… - ESMO Open, 2023 - esmoopen.com
Background Neratinib was approved as an extended adjuvant therapy by FDA in 2017 for
patients (pts) with HER2+ eBC and by the EMA in 2018 for pts with HER2+ HR+ eBC who …
patients (pts) with HER2+ eBC and by the EMA in 2018 for pts with HER2+ HR+ eBC who …
CLO23-051: Real-World Use of Neratinib in Patients With HER2-Positive Early-Stage Breast Cancer Following Prior Ado-Trastuzumab Emtansine (T-DM1) or Dual …
KE McCann, N Oestreicher, CG Rowan… - Journal of the National …, 2023 - jnccn.org
Background: Contemporary HER2-targeted agents revolutionized HER2-positive (HER2+)
early-stage breast cancer (ESBC) treatment, but real-world use patterns are largely …
early-stage breast cancer (ESBC) treatment, but real-world use patterns are largely …
Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial
MM Jimenez, FA Holmes, B Ejlertsen… - Annals of …, 2017 - annalsofoncology.org
Background: In the Herceptin Adjuvant (HERA) trial, 24% of patients (pts) who received T for
1 year (y) had a disease recurrence at 11 y follow-up. The primary analysis of the ExteNET …
1 year (y) had a disease recurrence at 11 y follow-up. The primary analysis of the ExteNET …
[HTML][HTML] Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
CH Barcenas, SA Hurvitz, JA Di Palma, R Bose… - Annals of …, 2020 - Elsevier
Background Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for
extended adjuvant treatment in early-stage HER2-positive breast cancer based on the …
extended adjuvant treatment in early-stage HER2-positive breast cancer based on the …
Duration of extended adjuvant therapy with neratinib in early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III …
M Gnant, H Iwata, AE Bashford, R Separovic, A Murias… - 2018 - ascopubs.org
524 Background: The optimal duration of adjuvant therapy with targeted agents remains a
question of ongoing relevance in oncology. ExteNET, an international, randomized, placebo …
question of ongoing relevance in oncology. ExteNET, an international, randomized, placebo …
119TiP A multicenter, open-label, single-arm, non-interventional real-world study to investigate the treatment patterns of neratinib in HER2-positive early breast cancer …
X Wang, F Ling, J Gao, J Ye, A Zhang, S Zhang… - ESMO Open, 2023 - esmoopen.com
Background Neratinib is an oral, irreversible tyrosine kinase inhibitor of HER1, HER2 and
HER4. In China, neratinib was approved in 2020 in the extended adjuvant treatment for …
HER4. In China, neratinib was approved in 2020 in the extended adjuvant treatment for …
75P Interim analysis (n= 150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in …
N Harbeck, D Wrobel, M Zaiss, D Guth… - Annals of …, 2022 - annalsofoncology.org
Background Neratinib is registered in Europe as extended adjuvant treatment for adult
patients with Human Epidermal Growth Factor Receptor 2-positive (HER2+) and Hormone …
patients with Human Epidermal Growth Factor Receptor 2-positive (HER2+) and Hormone …
The Neat-HER virtual registry: Updated results on HER2+ breast cancer patients receiving neratinib as extended adjuvant therapy.
GA Vidal, D Tripathy, N Hill, D Lalla, G Hanson… - 2021 - ascopubs.org
e13565 Background: Data from traditional registries are usually limited to patients treated at
study sites. Virtual registries can enroll a broader real-world population. Neat-HER is a US …
study sites. Virtual registries can enroll a broader real-world population. Neat-HER is a US …
[PDF][PDF] Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET …
FA Holmes, B Moy, S Delaloge… - Proceedings of the …, 2021 - pumabiotechnology.com
Background■ Neratinib (NERLYNX®), a small-molecule irreversible pan-HER tyrosine
kinase inhibitor (TKI), significantly improves invasive disease-free survival (iDFS) compared …
kinase inhibitor (TKI), significantly improves invasive disease-free survival (iDFS) compared …